MiMedx Group, Inc.
$3.25
▼
-0.76%
2026-04-21 08:06:01
www.mimedx.com
NCM: MDXG
Explore MiMedx Group, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$507.35 M
Current Price
$3.25
52W High / Low
$7.99 / $3.31
Stock P/E
10.44
Book Value
$1.73
Dividend Yield
—
ROCE
22.95%
ROE
21.61%
Face Value
—
EPS
$0.32
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
808
Beta
1.65
Debt / Equity
8.78
Current Ratio
4.32
Quick Ratio
3.92
Forward P/E
15.03
Price / Sales
1.37
Enterprise Value
$431.36 M
EV / EBITDA
5.48
EV / Revenue
1.03
Rating
None
Target Price
$9.67
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
- Valuation is not stretched on P/E basis.
Cons
- Some data points may be missing or delayed because the source is not an official exchange feed.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Cardiff Oncology, Inc. | $1.78 | — | $123.06 M | — | -107.63% | -71.45% | $4.55 / $1.48 | $0.66 |
| 2. | Dyadic International, Inc. | $0.88 | — | $31.88 M | — | -114.18% | -3.98% | $1.35 / $0.65 | $0.03 |
| 3. | Artiva Biotherapeutics, Inc. | $13.39 | — | $310.19 M | — | -76.21% | -56.55% | $13.2 / $1.47 | $4.53 |
| 4. | CEL-SCI Corporation | $3.94 | — | $33.32 M | — | -107.75% | -2.12% | $13.48 / $1.98 | $1.38 |
| 5. | Aligos Therapeutics, Inc. | $6.51 | — | $41.33 M | — | -130.74% | -1.97% | $13.69 / $4.2 | $8.67 |
| 6. | Impact BioMedical Inc. | $0.68 | — | $67.48 M | — | -26.29% | -1.04% | $1.95 / $0.36 | $0.12 |
| 7. | Puma Biotechnology, Inc. | $7.37 | 12.05 | $374.96 M | — | 27.62% | 27.97% | $7.9 / $2.75 | $2.59 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 118.09 M | 113.72 M | 98.61 M | 88.2 M | 92.91 M | — |
| Operating Profit | 21.08 M | 22.19 M | 12.37 M | 8.25 M | 11.15 M | — |
| Net Profit | 15.19 M | 16.75 M | 9.62 M | 7.02 M | 7.44 M | — |
| EPS in Rs | 0.1 | 0.11 | 0.06 | 0.05 | 0.05 | 0.05 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 418.63 M | 348.88 M | 321.48 M | 267.84 M |
| Operating Profit | 63.89 M | 59.31 M | 37.12 M | -14.73 M |
| Net Profit | 48.58 M | 42.42 M | 58.23 M | -30.2 M |
| EPS in Rs | 0.33 | 0.29 | 0.39 | -0.2 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 342.65 M | 263.92 M | 239.05 M | 171.43 M |
| Total Liabilities | 86.11 M | 70.81 M | 96.33 M | 189.42 M |
| Equity | 256.55 M | 193.11 M | 142.72 M | -17.99 M |
| Current Assets | 277.47 M | 191.89 M | 164.26 M | 134.2 M |
| Current Liabilities | 64.27 M | 45.59 M | 46.01 M | 43.56 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 74 M | 66.2 M | 26.77 M | -17.89 M |
| Investing CF | -6.89 M | -9.58 M | -2.15 M | -2.66 M |
| Financing CF | -5.41 M | -34.2 M | -8.57 M | -0.58 M |
| Free CF | 72.97 M | 64.52 M | 24.79 M | -19.41 M |
| Capex | -1.03 M | -1.68 M | -1.99 M | -1.51 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 8.52% | 20.03% | — | — |
| Earnings Growth % | -27.15% | 292.83% | — | — |
| Profit Margin % | 12.16% | 18.11% | -11.27% | — |
| Operating Margin % | 17% | 11.55% | -5.5% | — |
| Gross Margin % | 82.78% | 83.01% | 81.96% | — |
| EBITDA Margin % | 18.73% | 12.61% | -3.99% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.